UroGen Pharma Ltd.'s SEC filings document operating results, product revenue disclosures, financing agreements and governance matters for a biotechnology company focused on urothelial and specialty cancers. Recent 8-K reports furnish quarterly and annual financial results tied to JELMYTO and ZUSDURI, commercial launch updates, research and development expenses, reimbursement matters and pipeline disclosures involving UGN-103 and UGN-501.
Other filings describe material definitive agreements, including term-loan refinancing and credit arrangements with BioPharma Credit entities, as well as capital-structure information for ordinary shares listed on Nasdaq. Definitive proxy statements cover board matters, executive compensation, equity awards, pay-versus-performance tables and shareholder voting matters.
UroGen Pharma Ltd. director Leana Wen reported receiving new equity awards as part of her compensation. She was granted 8,000 restricted stock units, each representing a right to receive one ordinary share, and 10,000 stock options to purchase ordinary shares at an exercise price of $34.99 per share.
The RSUs and the shares underlying the options will vest in equal quarterly installments over one year, contingent on her continued service under the company’s 2017 Equity Incentive Plan. These are grants and do not involve any open-market buying or selling of shares.
UroGen Pharma Ltd. director Arie Belldegrun received a grant of stock options covering 20,000 ordinary shares. These options were granted at an exercise price of $34.99 per share and expire on June 22, 2036. The underlying 20,000 ordinary shares will vest in equal quarterly installments over one year, subject to the director maintaining Continuous Service under the company’s 2017 Equity Incentive Plan. After this grant, the filing shows 20,000 derivative securities held directly, with no additional option positions listed.
UroGen Pharma Ltd. reported results of its 2026 Annual Meeting of Shareholders. Investors approved amended and restated Articles of Association that, among other changes, tie eligibility for shareholder proposals to requirements under Israeli Companies Law.
Shareholders also approved a Compensation Policy Amendment related to directors’ and officers’ insurance and an amendment to the 2017 Equity Incentive Plan to increase ordinary shares authorized for issuance under the plan by 1,000,000 shares. All seven director nominees were elected, executive pay received advisory approval, and PricewaterhouseCoopers LLP was ratified as independent auditor until the 2027 annual meeting.
UroGen Pharma Ltd. reported a Form 144 notice showing the sale of 10,000 shares of common stock. The filing lists the sale date as 05/08/2026 with aggregate proceeds of $300,048.00. The underlying shares were issued on 01/27/2023 following a stock option exercise.
UroGen Pharma’s Chief Medical Officer Mark Schoenberg reported routine equity compensation activity. On June 8, he exercised restricted stock units (RSUs) covering 10,000 ordinary shares, converting them into stock at no exercise price. On the same date, 5,222 ordinary shares were sold at $27.30 per share to satisfy withholding tax obligations tied to this RSU settlement, according to the footnotes. After these transactions, Schoenberg directly held 139,763 ordinary shares of UroGen Pharma.
Mark Schoeberg reported a sale of 10,000 ordinary shares of UroGen Pharma Ltd. The sale is listed with a transaction date of 05/08/2026 and an associated value of 300,048.00. The filing also shows 30,000 ordinary shares issued upon vesting of RSUs on 06/08/2023 (no consideration).
UroGen Pharma reported that it has entered a settlement and license agreement with Teva Pharmaceuticals resolving patent litigation over Jelmyto, its mitomycin-based treatment for upper tract urothelial cancer. Teva had filed an Abbreviated New Drug Application seeking to market a generic Jelmyto before UroGen’s patents expired.
Under the agreement, UroGen will grant Teva a non-exclusive license to sell a generic version of Jelmyto in the United States starting on September 15, 2030, if it receives U.S. Food and Drug Administration approval and subject to certain customary conditions. All related patent cases in the U.S. District Court for the District of Delaware will be terminated, and the agreement will be reviewed by the U.S. Federal Trade Commission and the U.S. Department of Justice.
UroGen Pharma director James A. Robinson Jr. exercised restricted stock units into ordinary shares, increasing his direct share ownership. He acquired 2,000 ordinary shares through an RSU conversion and now directly holds 6,000 ordinary shares, with 2,000 RSUs remaining outstanding as a separate derivative holding.
UroGen Pharma Ltd. reports passive beneficial ownership disclosures by Paradigm BioCapital entities and Senai Asefaw as of 03/31/2026. The filing lists specific share holdings, including 1,703,949 shares reported for Paradigm BioCapital Advisors and related parties and 1,501,473 shares for Paradigm BioCapital International Fund Ltd.
The filing states these holdings represent 3.5% and 3.1% of the class respectively, calculated from 48,708,280 Ordinary Shares outstanding as of 03/31/2026 per the issuer's Form 10-Q. Reporting persons disclaim ownership beyond the shares directly held.